Articles

Exploring the highs and lows of IOLs during 2007.

blah

blah

Femtosecond lasers, safe, predictable and increasing in popularity but where will the industry go from here?

blah

A look back at what happened in the fields of cataract & refractive surgery in 2007 and what we can look forward to in 2008.

A look at imaging and diagnostics during 2007 and what the future holds.

blah

blah

blah

A look back at what has happened in the field of glaucoma in 2007 and what we can look forward to in 2008.

The World Economic Forum has selected 39 companies as Technology Pioneers for 2008 and NuLens is one of those honoured with this title.

blah

With additional training, optometrists are at least as accurate as junior ophthalmologists in diagnosing glaucoma.

Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.

OPKO Health has completed its acquisition of Ophthalmic Technologies Inc. (OTI), a privately owned Canadian company.

OccuLogix has announced that it is indefinitely suspending its RHEO System clinical development programme in dry age-related macular degeneration (AMD).

Barry G. Caldwell has been named as the new President and Chief Executive Officer of STAAR Surgical.

The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.

Fovea Pharmaceuticals has entered into a collaborative research agreement with Genzyme Corporation.

Monocyte chemoattractant protein 1 (MCP-1) seems to be responsible for apoptosis of the photoreceptors in certain visual disorders.

Have a look at the AMD therapies taking the first step along the path to approval.

What therapies have made it to Phase II clinical trials?

Take a look at the therapies that have reached Phase III clinical testing.

Take a look at the therapies that have already reached the market.

What are doctors using off-label to treat their AMD patients?

Terms & Conditions

Read Ophthalmology Times' extensive coverage from the 2007 annual meeting in New Orleans, USA.

Intravitreal bevacizumab (Avastin) performs better than verteporfin photodynamic therapy (PDT) in the management of choroidal neovascularization (CNV) in age-related macular degeneration.

Ophtherion has licensed the worldwide rights to develop diagnostic products for age-related macular degeneration (AMD) associated with specific variations in genes on Chromosome 10, from the University of Pittsburgh, USA.